Russia has announced progress in developing a cancer vaccine called Enteromix, which its officials claim demonstrated “high efficacy” during preclinical trials. Veronika Skvortsova, head of the Russian Federal Medical-Biological Agency (FMBA), stated at the Eastern Economic Forum that the vaccine is “ready for use” and awaits official approval. Preclinical results reportedly confirmed safety and significant effectiveness, though claims of 100% efficacy remain unverified.

The vaccine targets colorectal cancer and has shown “promising progress” in developing treatments for glioblastoma and melanoma, according to a report by Russian news agency TASS. However, medical experts caution that preclinical trials in animals do not guarantee human success. Dr. David James Pinato, a clinician scientist at Imperial College London, emphasized that animal model results “do not reproduce the complexity of the cancer genome or the human immune system,” urging further clinical testing.

Russia’s FMBA has not provided detailed data to substantiate its claims, leaving the scientific community skeptical about the vaccine’s actual potential. The agency continues to advance its research while facing scrutiny over the transparency of its findings.